Canton Strategic (CNTN) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nkarta (NKTX) has outperformed Canton Strategic (CNTN) over the past year, gaining 6.2% versus a loss of 34.6%. Canton Strategic is the larger company by market cap ($175.3 million vs $154.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | NKTX |
|---|---|---|
| Share price | $2.20 | $2.16 |
| Market cap | $175.30M | $154.35M |
| 1-day change | +5.77% | -2.93% |
| YTD return | -31.35% | +20.00% |
| 1-year return | -34.59% | +6.22% |
| 5-year return | — | -87.90% |
| EPS (TTM) | $-0.10 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.89 | $3.72 |
| 52-week low | $1.75 | $1.70 |
| Distance from 52-week high | -68.07% | -42.07% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +402.55% |
| Average volume | 758.86K | 613.16K |
| Shares outstanding | 79.68M | 71.62M |
| Employees | 12 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed CNTN by 40.8 percentage points over the past year.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
CNTN vs NKTX FAQ
Which is bigger, Canton Strategic or Nkarta?
Canton Strategic (CNTN) is larger, with a market capitalization of $175.30M compared with $154.35M for Nkarta (NKTX).
Which stock has performed better over the past year, CNTN or NKTX?
NKTX returned +6.22% over the past 12 months, compared with -34.59% for CNTN (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.